Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus PYRILAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus PYRILAMINE MALEATE.
HISTAFED vs PYRILAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Pyrilamine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby preventing histamine-mediated effects such as increased vascular permeability, vasodilation, and bronchoconstriction.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
25-50 mg orally every 6-8 hours as needed, not to exceed 200 mg per day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Approximately 16-23 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily renal as metabolites; about 80-90% excreted in urine within 24 hours, with less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine